[
    [
        {
            "time": "",
            "orginal_text": "天坛生物（600161）：销售端拓展力度加大，业绩略超预期【中报点评|西南医药朱国广陈铁林团队】",
            "features": {
                "keywords": [
                    "天坛生物",
                    "销售端",
                    "业绩",
                    "超预期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "天坛生物（600161）：销售端拓展力度加大，业绩略超预期【中报点评|西南医药朱国广陈铁林团队】",
            "scores": {
                "News_content": "天坛生物（600161）：销售端拓展力度加大，业绩略超预期【中报点评|西南医药朱国广陈铁林团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "天坛生物：血制品行业龙头，长期增长前景确定，维持增持评级",
            "features": {
                "keywords": [
                    "天坛生物",
                    "血制品",
                    "行业龙头",
                    "增长前景",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "天坛生物：血制品行业龙头，长期增长前景确定，维持增持评级",
            "scores": {
                "News_content": "天坛生物：血制品行业龙头，长期增长前景确定，维持增持评级",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "【国信医药|半年报点评】天坛生物：业绩高增长，现金流充沛",
            "features": {
                "keywords": [
                    "天坛生物",
                    "业绩",
                    "高增长",
                    "现金流"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "【国信医药|半年报点评】天坛生物：业绩高增长，现金流充沛",
            "scores": {
                "News_content": "【国信医药|半年报点评】天坛生物：业绩高增长，现金流充沛",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "天坛生物2019年中报点评:业绩高增长,现金流充沛",
            "features": {
                "keywords": [
                    "天坛生物",
                    "2019年",
                    "中报",
                    "业绩",
                    "高增长",
                    "现金流"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "天坛生物2019年中报点评:业绩高增长,现金流充沛",
            "scores": {
                "News_content": "天坛生物2019年中报点评:业绩高增长,现金流充沛",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]